stockrowUrogen Pharma
URGN Healthcare Biotechnology
Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024.
- Revenue
- +223.9%
- EPS
- +95.8%
- Free cash flow
- +64.0%
- Total debt
- +57.2%
Quarter to September 2026, against a year earlier
Follow URGN
Alert me
Urogen Pharma (URGN) EV/Sales
As of 6 November 2026, Urogen Pharma (URGN) trades at a EV/Sales of 5.4×. Over the past ten years it has ranged from 0.0× (March 2018) to 858× (December 2019); the current reading is higher than 40% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.3× | 173.35% |
| FY2024 | 3.8× | (38.97%) |
| FY2023 | 6.2× | 105.01% |
| FY2022 | 3.0× | 18.05% |
| FY2021 | 2.6× | (89.63%) |
| FY2020 | 24.6× | (96.97%) |
| FY2019 | 812× | 58.82% |
| FY2018 | 511× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 8.6× | (16.10%) |
| Jun 2026 | 10.3× | 51.69% |
| Mar 2026 | 6.8× | (34.33%) |
| Dec 2025 | 10.3× | 4.37% |
| 30 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| GHRS GH Research PLC compare | n/m |
| LBRX LB Pharmaceuticals Inc compare | n/m |
| KARD KARDIGAN INC compare | n/m |
| MNKD MannKind Corporation compare | 3.8× |
| URGN Urogen Pharma | 5.4× |
| OMER Omeros Corporation compare | 12.3× |
| NKTR Nektar Therapeutics compare | 19.2× |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 1,025× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)